120
M41 A62 K65 D67 T69 K70 L74 V75 F77 Y115 F116 Q151 M184 L210 T215 K219
NRTI
L V R N ins R, E V I L F Y M V, I W Y, F Q, E
V90 A98 L100 K101 K103 V106 V108 E138 V179 Y181 Y188 G190 P225 M230
F, T I, V H, C S
M, I
E, P
NNRTI
I G I H, N A, I A D, C, L, A, H L
Reverse transcriptase L10 V11 I13 G16 K20 L24 D30 V32 L33 E34 E35 M36 K43 M46 I47 G48 I50 F53 I54 Q58 D60 I62 L63 I64 H69 A71 G73 T74 L76 V77 V82 N83 I84 I85 N88 L89 L90 I93
F, R, I, V, C I V E R, M, I, T, V I N I I, F, V Q G I, L, V T I, L V, A V V, L L, Y V, M, L, T, S, A E E V P L, M, V K V, I, T, L S, T, C, A P V I A, T, F, S, I, L D V V D, S V M L, M
Protease
The following codons and amino acids have been classified as resistance (IAS):
7KH UHVLVWDQFH PXWDWLRQV KDYH EHHQ FODVVL¿HG DFFRUGLQJ WR WKH ³8SGDWH RI WKH 'UXJ 5HVLVWDQFH 0XWDWLRQV LQ +,9 'HFHPEHU ´ IURP WKH ,QWHUQDWLRQDO $,'6 6RFLHW\ 86$ KWWS LDVXVD RUJ UHVLVWDQFHBPXWDWLRQV PXWDWLRQVB¿JXUHV SGI
Frequency of NRTI-associated resistance mutations
0 1 0 1
Codon 77 Codon 115 Codon 116 Codon 151
(0,3%)
(0,0%)
(0,3%)
(0,0%)
(0,3%)
(3,8%)
(6,2%)
(4,1%)
14
1
Codon 75
(1,1%)
Codon 219
4
Codon 74
(3,8%)
23
14
Codon 70
(0,0%)
Codon 215
0
Codon 69
(6,5%)
15
24
Codon 67
(0,0%)
Codon 210
0
Codon 65
(0,0%)
37 (10,0%)
0
Codon 62
(5,4%)
Codon 184
20
51 (13,8%)
N = 370
Deceased since 1997, NRTI use
Codon 41
Resistance to NRTI
All centers
50
135
71
195
3
3
5
4
4
23
87
2
123
14
17
122
(2,4%)
(6,4%)
(3,3%)
(9,2%)
(0,1%)
(0,1%)
(0,2%)
(0,2%)
(0,2%)
(1,1%)
(4,1%)
(0,1%)
(5,8%)
(0,7%)
(0,8%)
(5,7%)
292 (13,7%)
N = 2124
Current cohort and NRTI use ever
121
7KH WDEOH VKRZV WKH QXPEHUV RI SDWLHQWV ZLWK 157, DVVRFLDWHG UHVLVWDQFH PXWDWLRQV DPRQJ DOO SDWLHQWV ZKR KDYH HYHU EHHQ WUHDWHG ZLWK 1XFOHRVLGH 5HYHUVH 7UDQVFULSWDVH ,QKLELWRUV ³157,´
13.2.1.1 Overview
13.2.1
³&XPXODWLYH UHVLVWDQFH´ LQFOXGHV DQ\ PXWDWLRQ HYHU IRXQG LQ D SDUWLFXODU SDWLHQW
'(),1,7,21 2) 5(6,67$1&( 81'(5 $57
Basics: 7KH UDWH RI UHVLVWDQFH GHYHORSPHQW GXULQJ DQWLUHWURYLUDO WKHUDS\ ³SHUFHQW ZLWK UHVLVWDQFH´ FRUUHVSRQGV WR WKH QXPEHU RI SDWLHQWV ZLWK UHVLVWDQFH PXWDWLRQV LQ UHODWLRQ WR WKH QXPEHU RI SDWLHQWV RQ $57 VHH DOVR FKDSWHU 0RVW JHQRW\SLF UHVLVWDQFH WHVWV DUH SHUIRUPHG DW WKH ,QVWLWXWH RI 9LURORJ\ DW WKH 0HGLFDO 8QLYHUVLW\ 9LHQQD
)5(48(1&< 2) 5(6,67$1&(
13. RISKS OF ANTIRETROVIRAL THERAPY